NZ589691A - Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders - Google Patents
Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disordersInfo
- Publication number
- NZ589691A NZ589691A NZ589691A NZ58969109A NZ589691A NZ 589691 A NZ589691 A NZ 589691A NZ 589691 A NZ589691 A NZ 589691A NZ 58969109 A NZ58969109 A NZ 58969109A NZ 589691 A NZ589691 A NZ 589691A
- Authority
- NZ
- New Zealand
- Prior art keywords
- piperidin
- thiazol
- disorders
- compounds
- octahydro
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 208000035475 disorder Diseases 0.000 title abstract 4
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 230000002337 anti-port Effects 0.000 title 1
- 210000001035 gastrointestinal tract Anatomy 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 102000008645 11-beta-Hydroxysteroid Dehydrogenase Type 1 Human genes 0.000 abstract 1
- 108010088011 11-beta-Hydroxysteroid Dehydrogenase Type 1 Proteins 0.000 abstract 1
- DNESMUNOEGXHTQ-UHFFFAOYSA-N 2-(1-butylsulfonylpiperidin-4-yl)-n-cyclohexyl-n-cyclopropyl-1,3-thiazole-4-carboxamide Chemical compound C1CN(S(=O)(=O)CCCC)CCC1C1=NC(C(=O)N(C2CC2)C2CCCCC2)=CS1 DNESMUNOEGXHTQ-UHFFFAOYSA-N 0.000 abstract 1
- MKZMBJQNLLGAJR-UHFFFAOYSA-N 2-(4-methoxyphenyl)-1-[4-[4-(piperidine-1-carbonyl)-1,3-thiazol-2-yl]piperidin-1-yl]ethanone Chemical compound C1=CC(OC)=CC=C1CC(=O)N1CCC(C=2SC=C(N=2)C(=O)N2CCCCC2)CC1 MKZMBJQNLLGAJR-UHFFFAOYSA-N 0.000 abstract 1
- HSNSEQPNQAPRFS-UHFFFAOYSA-N 3,4,4a,5,6,7,8,8a-octahydro-2h-quinolin-1-yl-[2-[1-(2-cyclohexylethyl)piperidin-4-yl]-1,3-thiazol-4-yl]methanone Chemical compound C1CCC2CCCCC2N1C(=O)C(N=1)=CSC=1C(CC1)CCN1CCC1CCCCC1 HSNSEQPNQAPRFS-UHFFFAOYSA-N 0.000 abstract 1
- FTLJSDWQAVGUFR-UHFFFAOYSA-N 4-[4-(3,4,4a,5,6,7,8,8a-octahydro-2h-quinoline-1-carbonyl)-1,3-thiazol-2-yl]-n-propan-2-ylpiperidine-1-carboxamide Chemical compound C1CN(C(=O)NC(C)C)CCC1C1=NC(C(=O)N2C3CCCCC3CCC2)=CS1 FTLJSDWQAVGUFR-UHFFFAOYSA-N 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000010412 Glaucoma Diseases 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 206010024229 Leprosy Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 206010033645 Pancreatitis Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000017442 Retinal disease Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 229940124639 Selective inhibitor Drugs 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 239000008103 glucose Substances 0.000 abstract 1
- 201000001421 hyperglycemia Diseases 0.000 abstract 1
- 208000026278 immune system disease Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- ZPDMLTWBZHWLIC-UHFFFAOYSA-N n-cyclohexyl-n-cyclopropyl-2-[1-(4-fluorophenyl)sulfonylpiperidin-4-yl]-1,3-thiazole-4-carboxamide Chemical compound C1=CC(F)=CC=C1S(=O)(=O)N1CCC(C=2SC=C(N=2)C(=O)N(C2CC2)C2CCCCC2)CC1 ZPDMLTWBZHWLIC-UHFFFAOYSA-N 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000003955 neuronal function Effects 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 208000033808 peripheral neuropathy Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 150000007979 thiazole derivatives Chemical class 0.000 abstract 1
- 201000008827 tuberculosis Diseases 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
- 230000002792 vascular Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08290424 | 2008-05-05 | ||
| PCT/EP2009/002607 WO2009135581A2 (en) | 2008-05-05 | 2009-04-08 | Novel nip thiazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ589691A true NZ589691A (en) | 2012-11-30 |
Family
ID=40935480
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ589691A NZ589691A (en) | 2008-05-05 | 2009-04-08 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8546575B2 (enExample) |
| EP (1) | EP2271405B1 (enExample) |
| JP (1) | JP5735412B2 (enExample) |
| KR (1) | KR101604366B1 (enExample) |
| CN (1) | CN102015026B (enExample) |
| AR (1) | AR072666A1 (enExample) |
| AU (1) | AU2009243812B2 (enExample) |
| BR (1) | BRPI0911497B8 (enExample) |
| CA (1) | CA2723431C (enExample) |
| CO (1) | CO6331305A2 (enExample) |
| EA (2) | EA201300759A1 (enExample) |
| EC (1) | ECSP10010656A (enExample) |
| ES (1) | ES2432383T3 (enExample) |
| IL (1) | IL208989A (enExample) |
| MX (1) | MX2010011917A (enExample) |
| NZ (1) | NZ589691A (enExample) |
| WO (1) | WO2009135581A2 (enExample) |
| ZA (1) | ZA201008723B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2008257693B2 (en) * | 2007-06-01 | 2011-01-27 | F. Hoffmann-La Roche Ag | Piperidine-amide derivatives |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2015005305A1 (ja) | 2013-07-09 | 2015-01-15 | 小野薬品工業株式会社 | Ａｌｘｒ作動化合物 |
| CN104910083A (zh) * | 2015-07-13 | 2015-09-16 | 佛山市赛维斯医药科技有限公司 | 烷氧苯基三氮唑亚砜类11β-HSD1抑制剂、制备方法及其用途 |
| CN104910084A (zh) * | 2015-07-13 | 2015-09-16 | 佛山市赛维斯医药科技有限公司 | 末端胺基取代的三氮唑亚砜类化合物、其制备方法及其用途 |
| EP3235813A1 (en) | 2016-04-19 | 2017-10-25 | Cidqo 2012, S.L. | Aza-tetra-cyclo derivatives |
| BR112020004356A2 (pt) * | 2017-09-08 | 2020-12-01 | Pi Industries Ltd. | novos compostos heterocíclicos fungicidas |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7754709B2 (en) * | 2003-06-10 | 2010-07-13 | Solvay Pharmaceuticals Bv | Tetracyclic thiophenepyrimidinone compounds as inhibitors of 17β hydroxysteroid dehydrogenase compounds |
| US20070231263A1 (en) * | 2004-04-13 | 2007-10-04 | Jun Qiu | Human G protein-coupled receptor and modulators thereof for the treatment of hyperglycemia and related disorders |
| EP1637529A1 (en) * | 2004-09-20 | 2006-03-22 | 4Sc Ag | Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof |
| DE102006010923A1 (de) | 2006-03-09 | 2007-09-13 | Saltigo Gmbh | Verfahren zur Herstellung von Chlor-1,4-dimethoxybenzol |
| EP1994017A2 (en) | 2006-03-15 | 2008-11-26 | 4Sc Ag | Novel heterocyclic nf-kb inhibitors |
| BRPI0709595A2 (pt) * | 2006-03-15 | 2011-07-19 | 4Sc Ag | inibidores de nf-kapab heterocìclicos |
-
2009
- 2009-04-08 WO PCT/EP2009/002607 patent/WO2009135581A2/en not_active Ceased
- 2009-04-08 EP EP09741800.8A patent/EP2271405B1/en active Active
- 2009-04-08 KR KR1020107027260A patent/KR101604366B1/ko not_active Expired - Fee Related
- 2009-04-08 MX MX2010011917A patent/MX2010011917A/es active IP Right Grant
- 2009-04-08 NZ NZ589691A patent/NZ589691A/xx not_active IP Right Cessation
- 2009-04-08 CN CN200980116875.5A patent/CN102015026B/zh not_active Expired - Fee Related
- 2009-04-08 CA CA2723431A patent/CA2723431C/en active Active
- 2009-04-08 JP JP2011507806A patent/JP5735412B2/ja not_active Expired - Fee Related
- 2009-04-08 ES ES09741800T patent/ES2432383T3/es active Active
- 2009-04-08 EA EA201300759A patent/EA201300759A1/ru unknown
- 2009-04-08 EA EA201001737A patent/EA018920B1/ru not_active IP Right Cessation
- 2009-04-08 AU AU2009243812A patent/AU2009243812B2/en not_active Ceased
- 2009-04-08 BR BRPI0911497A patent/BRPI0911497B8/pt not_active IP Right Cessation
- 2009-04-08 US US12/991,016 patent/US8546575B2/en not_active Expired - Fee Related
- 2009-04-30 AR ARP090101563A patent/AR072666A1/es unknown
-
2010
- 2010-10-28 IL IL208989A patent/IL208989A/en active IP Right Grant
- 2010-10-29 CO CO10134879A patent/CO6331305A2/es not_active Application Discontinuation
- 2010-12-02 EC EC2010010656A patent/ECSP10010656A/es unknown
- 2010-12-03 ZA ZA2010/08723A patent/ZA201008723B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102015026A (zh) | 2011-04-13 |
| US8546575B2 (en) | 2013-10-01 |
| WO2009135581A9 (en) | 2010-11-11 |
| CN102015026B (zh) | 2015-11-25 |
| CA2723431A1 (en) | 2009-11-12 |
| AU2009243812A1 (en) | 2009-11-12 |
| WO2009135581A3 (en) | 2010-08-19 |
| BRPI0911497A2 (pt) | 2019-01-15 |
| IL208989A (en) | 2014-01-30 |
| CA2723431C (en) | 2016-11-22 |
| KR20110004468A (ko) | 2011-01-13 |
| AR072666A1 (es) | 2010-09-15 |
| JP2011521907A (ja) | 2011-07-28 |
| MX2010011917A (es) | 2010-11-26 |
| EA201001737A1 (ru) | 2011-06-30 |
| KR101604366B1 (ko) | 2016-03-17 |
| EP2271405A2 (en) | 2011-01-12 |
| WO2009135581A2 (en) | 2009-11-12 |
| BRPI0911497B8 (pt) | 2021-05-25 |
| CO6331305A2 (es) | 2011-10-20 |
| JP5735412B2 (ja) | 2015-06-17 |
| EA018920B1 (ru) | 2013-11-29 |
| BRPI0911497B1 (pt) | 2021-01-26 |
| EA201300759A1 (ru) | 2013-11-29 |
| IL208989A0 (en) | 2011-01-31 |
| EP2271405B1 (en) | 2013-07-24 |
| AU2009243812B2 (en) | 2014-06-05 |
| ECSP10010656A (es) | 2011-01-31 |
| ZA201008723B (en) | 2012-01-25 |
| US20110060007A1 (en) | 2011-03-10 |
| ES2432383T3 (es) | 2013-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL226046A (en) | 2 - ((r4, r1) –4– (4– (5– (benzo [d] oxazole-2-ylamino) pyridine-2-yl) phenyl) cyclohexyl) Acetic acid and its use in the preparation of a drug for glucose intolerance, diabetes Type 2 and obesity | |
| CN101321525B (zh) | 作为l-cpt1抑制剂的杂芳基取代的哌啶衍生物 | |
| TWI523852B (zh) | 經取代之唑衍生物、含彼之組合物及其用途 | |
| NZ592508A (en) | Pyrazine compounds as phosphodiesterase 10 inhibitors | |
| Cowart et al. | A new class of potent non-imidazole H3 antagonists: 2-aminoethylbenzofurans | |
| WO2008080988A3 (en) | Cyclopentanone derivatives, method of synthesis and uses thereof | |
| PE20090717A1 (es) | Derivados de quinolina como inhibidores de la pi3 quinasa | |
| NZ618134A (en) | Azaadamantane derivatives and their uses as nicotinic acetylcholine receptors ligands | |
| JP2008513514A5 (enExample) | ||
| WO2009017455A1 (en) | A new combination of (a) an alpha-4-beta-2 -neuronal nicotinic agonist and (b) a gsk3 inhibitor | |
| WO2008148868A8 (en) | Piperidine/piperazine derivatives | |
| RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
| JP2013507366A5 (enExample) | ||
| WO2009017453A1 (en) | New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958 | |
| Kong et al. | Recent developments of p38α MAP kinase inhibitors as antiinflammatory agents based on the imidazole scaffolds | |
| WO2010045303A3 (en) | Pyrrolidine, piperidine and piperazine derivatives and methods of use thereof | |
| US20140179698A1 (en) | Selective protein kinase inhibitors | |
| Hinklin et al. | Identification of a new class of glucokinase activators through structure-based design | |
| PT1940844E (pt) | Compostos e composições como inibidores de proteína-quinase | |
| BRPI0911497B8 (pt) | derivados de nip tiazol, seu processo de fabricação, medicamento, composição farmacêutica, e kit | |
| NZ597668A (en) | Novel gpr 119 agonists | |
| JP2008513405A5 (enExample) | ||
| JP5220848B2 (ja) | ピペリジンアミド誘導体 | |
| NZ608708A (en) | Novel gpr 119 agonists | |
| EP3366686A3 (en) | Inhibitors of diacylglycerol o-acyltransferase 1 (dgat-1) and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| LAPS | Patent lapsed |